Oncolytics Biotech, SAFC In Supply Pact

Oncolytics Biotech has entered into a commercial supply agreement with SAFC, a division of Sigma-Aldrich Corp., for the commercial manufacture of Oncolytics’ reovirus, Reolysin. SAFC will perform process validation, continue to supply clinical requirements, and will supply commercial material upon approval.

“As a leading global provider of high-quality and reliable biologics manufacturing services we are eager to work with companies focused on bringing novel products to market,” said Gilles Cottier, president of SAFC. “SAFC has worked closely with Oncolytics to develop, scale-up, and optimize manufacturing of REOLYSIN, advancing it to the commercial level.”

“This agreement represents a significant step forward in the drive to commercialize Reolysin as we prepare to produce expanded clinical supplies and build inventory for potential commercial sales,” said Dr. Matt Coffey, chief operating officer of Oncolytics. “Having worked with a recognized world leader on the efficient manufacture of Reolysin for several years now, we feel we are well positioned with this element of our overall plan to commercialize Reolysin.”